REGENERON PHARMACEUTICALS, INC. (REGN)
↓ Download CSV- Sector Manufacturing
- Incorporated NY
- Fiscal year ends Dec 31
In fiscal 2025, REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B, up 1.0% from the prior year. The company was profitable, with a net margin of 31.4%. It held $40.56B in total assets against $9.30B in total liabilities.
Key ratios (FY2025)
24.9%
Operating margin
31.4%
Net margin
14.4%
Return on equity
+1.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B |
| Cost of Revenue | — | — | — | — | — | — | $402.80M | $237.50M | — | — |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.50M |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B |
| Shareholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B |
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $812.70M | $535.20M |
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B |
| Capital Expenditures | $898.40M | $755.90M | $718.60M | $590.10M | $551.90M | $614.60M | $429.60M | $383.10M | $272.60M | $511.90M |
| Shares Outstanding | 108.60M | 115.10M | 113.70M | 113.50M | 112.20M | 115.10M | 114.60M | 114.80M | 115.90M | 116.30M |